| Disease | A CLINICAL TRIAL ASSESSING THE EFFECTS OF GINKGO BILOBA EXTRACT ON DEMENTIA OF THE ALZHEIMER TYPE. THE TRIAL WAS A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PARALLEL-GROUP DESIGN IN 20 OUTPATIENTS. THE DURATION OF TREATMENT WAS 3 MONTHS. THE
PRIMARY OUTCOME VARIABLE WAS THE SUN SCORE IN THE SKT-TEST FOR THE DETERMINATION OF ATTENTION AND MEMORY. OTHER PSYCHOMETRIC TESTS (TRAILMAKING TEST, ADAS, CGI) AND ELECTROPHYSIOLOGICAL INVSTIGATIONS (EEG TOPAGRAPHY) WERE EVALUATED
DESCRIPTIVELY. ALTHOUGH THE ACTIVE-TREATMENT GROUP, WITH A MEAN SUM SCORE OF 19.67 POINTS IN THE S.K.T., HAD A POORER BASELINE LEVEL THAN THE PLACEBO GROUP (18.11 POINTS), IT EXPERENCED AN IMVPROVEMENT TO 16.78 UNDER TREATMENT WITH EGB 761
WHEREAS THE PLACEBO GROUP DETERIORATED TO 18.89 POINTS. THE DIFFERENCES BETWEEN THE BASELINE AND FINAL VALUES FORMED THE BASIS FOR A STATISTICAL GROUP COMPARISON, WHICH GAVE A RESULT FAVORABLE TO EGB 761, AT A SIGNIFICANCE LEVEL OF P<.013.
IN ADDITION TO THIS PSYCHOMETRIC CONFIRMATION OF EFFICACY, CERTAIN DESCRIPTIVE TRENDS WERE FOUND AT THE PSYCHOPATHOLOGICAL (CLINICAL GLOBAL IMPRESSION) AND DYNAMIC FUNCTIONAL (EEG FINDINGS) LEVELS, WHICH CAN BE INTERPRETED AS EVIDENCE OF
EFFECTIVENESS OF GINKGO BILOBA SPECIAL EXTRACT EGB 761 IN MILD TO MODERATE DEMENTIA AND OF LOCAL EFFECTS IN THE CENTRAL NERVOUS SYSTEM. INTER-GROUP DIFFERENCES IN ADAS COGNITIVE AND NON-COGNITIVE SUBSCALES DID NOT REACH STATISTICAL
SIGNIFICANCE, PROBALY BECAUSE OF THE SMALL SAMPLE SIZE. |